These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15536687)

  • 41. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
    Rosell R; Ichinose Y; Taron M; Sarries C; Queralt C; Mendez P; Sanchez JM; Nishiyama K; Moran T; Cirauqui B; Mate JL; Besse B; Reguart N; Perez M; Sanchez JJ
    Lung Cancer; 2005 Oct; 50(1):25-33. PubMed ID: 16011858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
    Boldrini L; Alì G; Gisfredi S; Ursino S; Baldini E; Melfi F; Lucchi M; Comin CE; Maddau C; Tibaldi C; Camacci T; Servadio A; Mussi A; Fontanini G
    Oncol Rep; 2009 Oct; 22(4):683-91. PubMed ID: 19724844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The rational basis of using novel targeted biological agents in non-small cell lung cancer.
    Ciardiello F
    Suppl Tumori; 2002; 1(4):S31-3. PubMed ID: 12415813
    [No Abstract]   [Full Text] [Related]  

  • 44. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.
    Chang GC; Yang TY; Chen KC; Yin MC; Wang RC; Lin YC
    J Clin Oncol; 2004 Nov; 22(22):4646-8. PubMed ID: 15542815
    [No Abstract]   [Full Text] [Related]  

  • 45. EGFR pharmacogenomics: the story continues to mutate and evolve.
    Desai AA; Ratain MJ
    Am J Pharmacogenomics; 2005; 5(2):137-9. PubMed ID: 15813677
    [No Abstract]   [Full Text] [Related]  

  • 46. New driver mutations in non-small-cell lung cancer.
    Pao W; Girard N
    Lancet Oncol; 2011 Feb; 12(2):175-80. PubMed ID: 21277552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].
    Ren YL; Sheng J; Zhou XY; Fang Y; Pan HM
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):152-153. PubMed ID: 30862147
    [No Abstract]   [Full Text] [Related]  

  • 48. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
    Takano T; Ohe Y; Sakamoto H; Tsuta K; Matsuno Y; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Shibata T; Sakiyama T; Yoshida T; Tamura T
    J Clin Oncol; 2005 Oct; 23(28):6829-37. PubMed ID: 15998907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EGFR mutation in gefitinib-responsive small-cell lung cancer.
    Okamoto I; Araki J; Suto R; Shimada M; Nakagawa K; Fukuoka M
    Ann Oncol; 2006 Jun; 17(6):1028-9. PubMed ID: 16357019
    [No Abstract]   [Full Text] [Related]  

  • 50. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
    J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
    Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
    Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
    Endo K; Sasaki H; Yano M; Kobayashi Y; Yukiue H; Haneda H; Suzuki E; Kawano O; Fujii Y
    Oncol Rep; 2006 Sep; 16(3):533-41. PubMed ID: 16865253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
    Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
    Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
    Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O
    Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746
    [No Abstract]   [Full Text] [Related]  

  • 55. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
    Kozlov V; Karpov I; Kovalenko S; Shamanin V
    Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer.
    Glover KY; Perez-Soler R; Papadimitradopoulou VA
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):83-92. PubMed ID: 14981585
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lung cancer: looking ahead in 2004.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2004 Jan; 5(4):200. PubMed ID: 14967070
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.